Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal)

Technology appraisal
Reference number: TA240
Published: 14 December 2011
Last updated: 29 March 2017

History

Documents created during the development process.

Background information

Review decision - March 2015 information
Appendix A - RPP decision paper March 2015
Appendix A - RPP decision paper March 2015 (PDF 72 KB)

Published:

25 March 2015
Colorectal cancer (metastatic) - panitumumab (terminated appraisal): review proposal 9 February 2015 information
Colorectal cancer (metastatic)- panitumumab (terminated appraisal): appendix A matrix of stakeholders
Colorectal cancer (metastatic)- panitumumab (terminated appraisal): appendix A matrix of stakeholders (PDF 101 KB)

Published:

09 February 2015
Colorectal cancer (metastatic)- panitumumab (terminated appraisal): appendix B - GE proposal paper January 2015
Colorectal cancer (metastatic)- panitumumab (terminated appraisal): appendix B - GE proposal paper January 2015 (PDF 621 KB)

Published:

09 February 2015
TA176 Colorectal cancer (first line) - cetuximab and TA240 Colorectal cancer (metastatic) - panitumumab (terminated appraisal): review decision - January 2014 information
TA176 and TA240; Cetuximab and Panitumumab for the first-line treatment of metastatic colorectal cancer: appendix A - GE Decision Paper - January 2014
TA176 and TA240; Cetuximab and Panitumumab for the first-line treatment of metastatic colorectal cancer: appendix A - GE Decision Paper - January 2014 (PDF 230 KB)

Published:

27 January 2014

Colorectal cancer (metastatic) - panitumumab: letter to stakeholders about suspension

Colorectal cancer (metastatic) - panitumumab: letter to stakeholders about suspension
Colorectal cancer (metastatic) - panitumumab: letter to stakeholders about suspension (PDF 10 KB)

Published:

30 August 2011